Targeting Neuroinflammation in Central Nervous System Diseases by Oral Delivery of Lipid Nanoparticles

Pharmaceutics, Journal Year: 2025, Volume and Issue: 17(3), P. 388 - 388

Published: March 18, 2025

Neuroinflammation within the central nervous system (CNS) is a primary characteristic of CNS diseases, such as Parkinson’s disease, Alzheimer’s disease (AD), amyotrophic lateral sclerosis, and mental disorders. The excessive activation immune cells results in massive release pro-inflammatory cytokines, which subsequently induce neuronal death accelerate progression neurodegeneration. Therefore, mitigating neuroinflammation has emerged promising strategy for treatment diseases. Despite advancements drug discovery development novel therapeutics, effective delivery these agents to remains serious challenge due restrictive nature blood–brain barrier (BBB). This underscores need develop system. Recent studies have identified oral lipid nanoparticles (LNPs) approach efficiently deliver drugs across BBB treat neurological review aims comprehensively summarize recent LNPs designed controlled therapeutic modulation diseases through administration. Furthermore, this addresses mechanisms by overcome biological barriers evaluate their clinical implications efficacy context systems. Specifically, it focuses on LNP formulations that facilitate administration, exploring potential enhance bioavailability, improve targeting precision, alleviate or manage symptoms associated with range

Language: Английский

Dimethyl Fumarate Sterically Stabilized Solid Lipid Nanoparticles. Physicochemical properties and in vitro drug release

International Journal of Nanomaterials Nanotechnology and Nanomedicine, Journal Year: 2025, Volume and Issue: 11(1), P. 015 - 026

Published: Jan. 1, 2025

In this work Dimethyl Fumarate (DMF)-loaded and DMF-unloaded Solid Lipid Nanoparticles (SLNs) were developed characterized by Dynamic Light Scattering (DLS), Atomic Force Microscopy (AFM), Scanning Electron (SEM), Differential Calorimetry (DSC), X-ray Diffraction (XRD). vitro release assay was also performed, DMF quantified GC-MS. SLNs prepared a two-step methodology using hot nanoemulsification followed ultrasound irradiation. The results of the mean diameter, polydispersity, zeta potential in range 157 to 525 nm, 0.20 0.6, -30 -7mV, respectively. with spherical elliptical shapes evidenced AFM SEM techniques. XRD DSC analyses revealed strong interaction among SLN components significant loss crystallinity set these structured SLNs. Encapsulation efficiency up 99% loading capacity dependent on O/S ratio has been achieved. could be analyzed first-order kinetics.

Language: Английский

QbD-Employed Formulation and Characterization of Sacubitril-Loaded Solid Lipid Nanoparticles: A Step Forward in Nanotechnology-Based Delivery for Hypertension

Drug Development and Industrial Pharmacy, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 12

Published: April 23, 2025

To develop and characterize sacubitril-loaded solid lipid nanoparticles (SLNs) using a QbD approach to enhance stability, bioavailability, therapeutic efficacy for improved hypertension management. SAC-loaded SLNs were formulated central composite quadratic model within the framework. Characterization techniques, including transmission electron microscopy, differential scanning calorimetry, Fourier transform infrared spectroscopy, confirmed particle morphology, crystallinity, structural integrity. The in vitro antihypertensive activity was evaluated human aortic smooth muscle cells (HASMCs) via MTT assay, assessing cell viability inhibition rates. A novel reverse-phase high-performance liquid chromatography (RP-HPLC) method developed quality control, utilizing C18 column with methanol (80:20 v/v) mobile phase. optimized formulation exhibited size of 184 nm, zeta potential -28 mV, high entrapment efficiency (93.83%), sustained drug release (86.23% over 24 h). In studies demonstrated significant inhibiting hypertension-induced HASMCs, achieving 61.97% rate. Comparative analysis showed superior performance SAC-SLNs standard SAC, highlighting their as an advanced treatment option cardiovascular care RP-HPLC excellent sensitivity (LOD 0.96 µg/mL; LOQ 2.93 µg/mL), linearity (R2 = 0.998), ensuring robust control. are promising platform enhancing SAC delivery improving outcomes, addressing limitations traditional formulations advance therapy critical healthcare.

Language: Английский